chemoresistance

che·mo·re·sis·tance

(kē'mō-rē-zis'tants),
The resistance of bacteria or malignant cells to the inhibiting action of certain chemical substances used in treatment.
Farlex Partner Medical Dictionary © Farlex 2012

chemoresistance

1. Resistance of cells to the action of a specific therapeutic agent.
2. Resistance of a particular tumor to chemotherapy; treatment refractory.
McGraw-Hill Concise Dictionary of Modern Medicine. © 2002 by The McGraw-Hill Companies, Inc.

che·mo·re·sis·tance

(kē'mō-rē-zis'tăns)
The state of being resistant to a chemical.
Medical Dictionary for the Health Professions and Nursing © Farlex 2012
Mentioned in ?
References in periodicals archive ?
DelMar has demonstrated that VAL-083's anti-tumor activity is unaffected by common mechanisms of chemoresistance, including MGMT, in cancer cell models and animal studies.
She has discovered a mechanism of chemoresistance in metaplastic breast carcinoma, an aggressive subtype of triple-negative breast cancer.
In serous epithelial ovarian cancer, over-expression of Sirt1 contributes to chemoresistance and poor prognosis (17).
Key Study Results: Increased serum and tumor GAS6 levels are associated with chemoresistance and decreased progression free survival in patients with high-grade serous ovarian cancer undergoing neoadjuvant treatment.
Through data from their study, they have the potential to shed light on BMME mechanisms which may be involved in the development of chemoresistance in AML cells.
Diagnostic assessment of osteosarcoma chemoresistance based on virtual clinical trials.
For example, miR-101 could enhance paclitaxel (PTX)-induced apoptosis in NSCLC.[17] MiR-216b was able to sensitize NSCLC cells to cisplatin-induced apoptosis.[18] Moreover, miR-129-5p could also overcome resistance to cisplatin in NSCLC cells.[19] Hence, it would be interesting to investigate whether miR-125-1-3p also possesses the ability to overcome chemoresistance in NSCLC.
Its proprietary technology platform enables the development of highly specific monoclonal antibody therapeutics, including ADCs, targeting cancer cell surface glycans called TACAs, an emerging set of tumor-specific antigens implicated in immune suppression, chemoresistance, and a CSC phenotype.
Combination of progesterone was found to overcome autophagy-related chemoresistance and allowed effective cancer cell elimination (54).